Purpose: Irritability has been reported in epilepsy patients. We identified associated factors for interictal irritability in epilepsy patients. Method: Adult epilepsy patients who received antiepileptic drugs (AEDs) for at least 1 year were invited to participate in this study. For eligible patients, several questionnaires, such as the Irritability in Adult Patients with Epilepsy (I-Epi), the Korean version of the Neurological Disorders Depression Inventory for Epilepsy (K-NDDI-E), the Generalized Anxiety Disorder-7 (GAD-7), the Epworth Sleepiness Scale (ESS), and the Insomnia Severity Index (ISI), were administered. We investigated factors for determining the overall I-Epi score using univariate and multivariate analyses. Results: A total of 276 patients with epilepsy were included in the study. Mean duration of epilepsy was 15.4 years (2-58 years), and 146 patients (52.9%) had a seizure freedom for 1 year. Mean overall I-Epi score was 46.1 (18-105), and 163 patients (59.1%) had at least a moderate level of irritability. Although several factors, including demographic, socioeconomic, psychosomatic, epilepsy-related factors, and levetiracetam intake, were associated with the overall I-Epi score, the strongest factor was the K-NDDI-E score, followed by the ISI score, the GAD-7 score, the ESS score, seizure control, and duration of epilepsy. Conclusion: An appropriate management of psychosomatic problems and epileptic attacks is likely to reduce irritability in epilepsy patients. Acknowledgment of irritability by clinicians will reduce drug failure when they administer AEDs with negative psychotropic profiles, especially irritability and aggression.
Introduction
The daily living of epilepsy patients is affected not only by epileptic attacks but also by comorbid medical and/or psychiatric problems. Psychiatric problems such as depression and anxiety have been highlighted as important factors for determining quality of life in epilepsy patients [1] . Along the same line, it is worth noting that behavioral problems associated with psychosis, aggression, and irritability critically affect outcomes in persons with epilepsy (PWE) [1, 2] .
Irritability is defined as a mood of easy annoyance and touchiness. It is denoted by anger and temper outbursts [3] . Irritability subjectively makes patients unpleasant, and objectively impairs interpersonal relationships by expression of negative feelings [4] . Various aspects of epilepsy may induce irritability, including the epilepsy itself, underlying brain injury, and comorbid depression [1, 5] . In the case of the association with depression, irritability is an atypical symptom of depression that can be seen in many PWE [5] . Irritability is one of the common adverse effects associated with antiepileptic drugs (AEDs). Restlessness, aggressive feeling, nervousness, and agitation were reported in 30-75% of epilepsy patients who took AEDs [6, 7] . As we know, adverse effects of AEDs elicit poor compliance and finally induce seizure recurrence. Actually, some AEDs such as levetiracetam (LEV) and perampanel (PER) have been found by meta-analyses of randomized controlled trials to induce irritability as an adverse effect [8, 9] .
If we administer these drugs to patients with irritability, it is more likely to produce drug failure due to the accentuation of irritability. Therefore, it is critical for clinicians to acknowledge irritability and to identify its predictors before AED trials in PWE. Regarding these issues, we examined the frequency of interictal irritability and identified associated factors in PWE.
Methods

Subjects
Epilepsy patients who consecutively visited an epilepsy clinic at Kyungpook National University Hospital between November 2015 and April 2016 were invited to participate in the study. They were adults 18-70 years of age who took AEDs for at least 1 year. Epilepsy was diagnosed according to the criteria of the International League Against Epilepsy (ILAE) for seizures and epileptic syndromes [10] . Participants had the ability to provide informed consent and agree with the study protocol. We excluded subjects with severe neurological, psychiatric, or other disorders that prevented them from understanding the questionnaires and fully cooperating with the study. We also excluded patients who had an overt seizure in the 4 days preceding the start of the study.
Study design
This is a cross-sectional study that was approved by the Institutional Review Board of Kyungpook National University Hospital, and all subjects provided written informed consent before participation. One trained epileptologist interviewed all subjects and collected demographic, socioeconomic, and clinical information; the data were then added to a computerized database.
The demographic variables were age, gender, and education. The socioeconomic variables were employment status (employed versus unemployed), household income [at least one million Korean won (KRW) per month (equivalent to $900 USD per month) versus less than one million KRW per month], possession of a driver's license (yes versus no), and marital status (married versus divorced, widowed, or unmarried). The clinical variables were concurrent medical disease, age at onset of epilepsy, duration of epilepsy, type of seizure, epilepsy syndrome, magnetic resonance image (MRI) abnormality, family history of epilepsy, history of febrile convulsion, duration of AED intake, AED regimen, AED load, LEV intake, and seizure control.
Four categories of epileptic syndrome were used: temporal lobe epilepsy (TLE), extra TLE (epilepsy syndromes in which the epileptic attacks originated from the frontal, parietal, or occipital lobes), generalized epilepsy (GE), and unknown syndrome. The AED regimen was classified as monotherapy or polytherapy according to the number of AEDs taken by patients. AED load was estimated as the sum of the ratios of "prescribed daily dose (PDD)" over "defined daily dose (DDD)" for each AED in the regimen of individual patients [11] . The DDD means the assumed average daily maintenance dose for an AED [12] . We included LEV intake as a variable because LEV has been identified to induce irritability and aggression [6] . Patients who took LEV as monotherapy or polytherapy were included in the LEV intake group. We could not include PER intake as a variable because [13] was not introduced in Korea during the study period.
Epilepsy patients were classified into three subgroups based on the state of their seizure control: well-controlled epilepsy (WCE), poorly controlled epilepsy (PCE), and uncontrolled epilepsy (UCE). Well-controlled epilepsy was defined as freedom from seizures during the preceding year. Uncontrolled epilepsy was defined as an average of more than one seizure per month for 18 months and no seizure-free periods longer than 3 months, which were the criteria used to determine drug-refractory epilepsy as a failure in previous adequate trials of two AEDs [14] . Poorly controlled epilepsy was defined as an intermediate degree of seizure control that did not meet the criteria for WCE or UCE.
Questionnaires
Eligible subjects underwent several self-report questionnaires including the Irritability in Adult Patients with Epilepsy (I-Epi) [15] , the Korean version of the Neurological Disorders Depression Inventory for Epilepsy (K-NDDI-E) [16] , Generalized Anxiety Disorder-7 (GAD-7) [17] , Epworth Sleepiness Scale (ESS) [18] , and Insomnia Severity Index (ISI) [19] .
Irritability in Adult Patients with Epilepsy (I-Epi)
The I-Epi is an inventory to evaluate interictal irritability in epilepsy patients [13] . It was originally developed and validated for Italian epilepsy patients. The I-Epi has four main domains associated with irritability, which are Physical Functioning (PF), Verbal Functioning (VF), Epilepsy Functioning (EF), and Temperamental Functioning (TF). The domains have 3, 5, 5, and 5 items, respectively, and each item has a 6-point Likert scale in which 1 is "never," 2 is "almost never," 3 is "rarely," 4 is "sometimes," 5 is "often," and 6 is "always." Thus, the range of the overall I-Epi score is 18-108. The higher score of I-Epi means the more intense level of irritability. An overall I-Epi score less than 41 means a low level of irritability; between 41 and 64 means a moderate level of irritability; higher than 64 indicates a high level of irritability; above 89 indicates a pathological level of irritability. Cronbach's a of scores of the overall I-Epi, PF, VF, EF, and TF were 0.84, 0.45, 0.70, 0.63, and 0.49, respectively [15] . For our subjects, Cronbach's a of scores of the overall I-Epi, PF, VF, EF, and TF were 0.92, 0.62, 0.79, 0.8, and 0.71, respectively.
Korean version of the Neurological Disorders Depression Inventory for Epilepsy (K-NDDI-E)
The K-NDDI-E is a reliable, validated screening instrument for major depressive disorder (MDD) in Korean PWE [16] . This inventory includes six items using a four-point scale (1-4) to indicate how much the patients have been bothered by depression-related problems during the previous 2 weeks. Higher scores indicate more depressive symptoms. The Cronbach's a coefficient was 0.898, and a total score of 12 or more is suggestive of MDD.
Generalized Anxiety Disorder-7 (GAD-7)
The GAD-7 is a self-report questionnaire used for the rapid detection of generalized anxiety disorder (GAD) in Korean PWE [16] . Subjects are asked to rate seven items using a four-point scale (0-3) to indicate how much they have been bothered by anxietyrelated problems over the previous 2 weeks. Total scores range from 0 to 21, with a higher score indicating more intense anxiety.
The Cronbach's a coefficient was 0.924, and a total score of 7 or more is suggestive of GAD.
Epworth Sleepiness Scale (ESS)
The ESS is broadly used for the detection of daytime sleepiness, particularly among patients with sleep-disordered breathing [20, 21] . The inventory consists of eight items. Each item of the inventory asks about the sleep propensity in a specific situation of daily life. Therefore, the total ESS score means the average sleep propensity during daily life [22] . Each item is a 4-point Likert scale and ranges between 1 and 4 points; total ESS score ranges between 8 and 32 points. Higher scores indicate higher subjective sleepiness. The Cronbach's a coefficient of the Korean version of the ESS is 0.90 [18] .
Insomnia Severity Index (ISI)
The ISI measures the patient's perception of insomnia severity [23] . There are seven items to evaluate insomnia. Each item is a 5-point Likert scale ranging from 0 to 4 points; total ISI score ranges from 0 to 28 points. Higher scores indicate a higher degree of insomnia. The Cronbach's a coefficient of the Korean version of the ISI was 0.92, and a cutoff score of 15.5 was optimal for determining patients with insomnia [19] .
Statistical analysis
Frequency data were compared by Fisher exact test. To determine the relationship between the overall I-Epi score and independent variables, a Pearson's correlation coefficient was applied. Variables that were significantly correlated with the overall I-Epi score were included in multiple linear regression analyses with stepwise selection using entry and exit probabilities of 0.05 and 0.1, respectively. Collinearity statistical analysis was performed and the variance inflation factor (VIF) was measured. All statistical analyses were performed using SPSS (version 23, IBM Inc., Chicago, IL, USA). We used a significance level of p < 0.05 for all statistical measures.
Results
The present study initially included 351 epilepsy patients, but 75 were excluded for the following reasons: mental retardation (n = 26), refusal to complete the questionnaires (n = 18), severe neurological or other disorders (n = 12), being younger than 18 years of age (n = 6), being older than 70 years of age (n = 6), illiteracy (n = 4), and less than 1 year of AED treatment. Thus, 276 epilepsy patients were included in the final analyses of the present study.
Characteristics of eligible patients
Demographic, socioeconomic, clinical, and psychosomatic characteristics of eligible patients are summarized in Table 1 . Mean age of patients was 40.3 AE 12.8 (range, 18-70 years), and 62% of the patients were men. Mean age of epilepsy onset was 24.9 AE 13.0 (range, 1-63 years), and mean duration of epilepsy was 15.4 AE 11.1 (range, 2-58 years). The most common epileptic syndrome was TLE. Almost half of patients received AED monotherapy, and 42.0% of patients took LEV as mono-or polytherapy. For seizure control, 52.9% of patients had WCE, 29% of patients had PCE, and 18.1% of patients had UCE. Mean overall IEpi score was 46.1 AE16.2 (range, 18-105), and 59.1% of patients had at least a moderate level of irritability.
Level of irritability according to seizure control
The level of irritability with respect to seizure control is listed in Table 2 . More than 93% of patients with WCE had a low or a moderate level of irritability by the overall I-Epi score. On the other hand, three-quarters of patients with UCE manifested a moderate or a high level of irritability. The level of irritability was significantly correlated with seizure control (x 2 = 20.699, p < 0.01).
Variables correlated with the overall I-Epi score by univariate analyses
Variables that were significantly correlated with the overall IEpi score by univariate analyses are noted in Table 3 . The overall IEpi score was higher in patients from the following categories: lower education level, unemployment, lower household income, absence of driver's license, longer duration of epilepsy, partial seizure, longer duration of AED intake, polytherapy, higher AED load, LEV intake, poor seizure control, and higher scores on the K-NDDI-E, the GAD-7, the ESS, and the ISI. 
Factors associated with the overall I-Epi score by multivariate analyses
Factors associated with the overall I-Epi score by stepwise linear regression analyses are listed in Table 4 . The strongest factor was the K-NDDI-E score (ß = 0.272, p < 0.001), followed by the ISI score (ß = 0.206, p < 0.001), the GAD-7 score (ß = 0.177, p = 0.026), the ESS score (ß = 0.163, p = 0.001), seizure control (ß = 0.120, p = 0.009), and duration of epilepsy (ß = 0.101, p = 0.022). This sixvariable model explained 48.9% of the variance in the overall I-Epi score. The variance inflation factor (VIF) was less than 10 for all factors, suggesting that they exerted independent effects without redundancy.
Discussion
We found that almost 60% of epilepsy patients exhibited at least a moderate level of irritability. Several factors including demographic, socioeconomic, clinical, and psychosomatic factors were correlated with interictal irritability. However, critical factors associated with interictal irritability were depression, insomnia, anxiety, daytime sleepiness, uncontrolled seizure, and longer duration of epilepsy. With these results, we suggest that appropriate interventions for psychosomatic problems and epileptic attacks may reduce irritability in epilepsy patients.
Although irritability has been reported to have negative impact on epilepsy patients, there was no specific instrument to measure their irritability. Recently, an Italian hospital-based study developed and validated a new instrument, the I-Epi, for the assessment of interictal irritability in adult patients with epilepsy [13] . The authors found that the I-Epi was fairly high for psychometric properties. Mean score of the overall I-Epi was higher in Italian patients (53.4 AE 15.5) than in our patients (46.1 AE16.2), and the frequency of at least a moderate level of irritability was higher in Italian patients (75%) than in our patients (59.1%). We could not directly compare the impact of psychiatric problems on the level of irritability between the two studies due to the application of different measures for those problems. The proportion of uncontrolled seizure in Italian patients was similar with that of our patients. The duration of epilepsy was shorter in our patients than in the Italian patients. Sleep problems were not measured in Italian patients. The differences of the I-Epi score and frequency of irritability between the two countries might be attributed to many sociocultural factors including ethnicity.
We found that the level of irritability was closely related to seizure control. A low level of irritability was common in patients with WCE, but a moderate or high level of irritability was common in patients with PCE or UCE. As we easily understand, patients with uncontrolled seizure are more likely to have depression, sleep impairment, socioeconomic problems, stigma, social discrimination, and AED-related side effects than those with WCE. Under these circumstances, the level of irritability might be increased in patients with PCE or UCE. The interventions to reduce epileptic attacks may be helpful to decrease irritability of epilepsy patients.
Regarding the associated factors for irritability, we found that depression and anxiety were critical. Irritability and depression have a close and mutual relationship. Previous studies have shown that irritability is a risk factor for psychopathology such as depressive and anxiety disorders [24] [25] [26] . Inversely, irritability may frequently be part of depressive disorders in epilepsy patients [5] . A study to evaluate the safety of sertraline enrolled 100 consecutive epilepsy patients who had depressive or obsessive-compulsive disorders [5] . Depressive disorders were found in 97 of 100 patients; 69 of the depressed patients had pleomorphic features of depressive disorders. Among the pleomorphic features, irritability and poor frustration tolerance were most disabling symptoms in 36 of the 69 pleomorphic patients [5] . In an Italian hospital-based study, psychiatric disturbance was a critical factor for irritability [15] . Through these results, identification and appropriate intervention of psychiatric comorbidities can help epilepsy patients and lessen irritability. Individuals with disturbed sleep can also experience emotional instability expressed by a greater irritability, aggression, or hostility [27] . In our research, we first elucidated sleep problems as critical factors for irritability in epilepsy patients. As a mechanism for inducing irritability, sleep problems may impair prefrontal cortical functioning, thereby weakening the top-down inhibition of aggression or violence [13, 28] . In a review of the literature, authors reported that some individuals may be more vulnerable to the emotional consequences of poor sleep according to prefrontal cortical functioning or behavioral coping style [27] . If so, it is important to identify these individuals, because promoting good sleep in these people may ameliorate irritability or aggression. Epilepsy patients, especially those with uncontrolled seizures, are likely to belong to this risk group.
We found duration of epilepsy was a critical factor for irritability. As we know, longer duration of epilepsy is more likely to induce poor socioeconomic states, stigma, social discrimination, and longer AED exposure. Moreover, most patients with long duration of epilepsy are likely to have uncontrolled seizure, which elicits irritability. Because of these issues, it is important to manipulate seizures earlier to reduce irritability in epilepsy patients.
Although LEV intake was not a critical factor for irritability, it had a weak correlation with irritability. Some AEDs have been reported to induce irritability or aggression as an adverse effect in epilepsy patients [29] . Among the second generation of AEDs, LEV is representative of inducing irritability or aggression. For the third generation of AEDs, PER is representative of inducing irritability or aggression. In a meta-analysis of 26 randomized, controlled trialsfor evaluating adverse effects of LEVs, nervousness/irritability was significantly associated with LEV treatment [8] . Risk difference between patients with LEV treatment and controls with placebo was 0.06 (95% CI 0.02-0.09). The dose of LEV was not correlated with the occurrence of nervousness/irritability. In a meta-analysis of nine randomized, controlled trials for measuring adverse effects of PERs, irritability was significantly associated with the dose of PER, especially 12 mg/day [9] . The risk difference with placebo controls was 0.09 (95% CI 0.02-0.16). In a review of pooled data about the safety endpoints in three phase III trials of PERs, the frequency of irritability was 11.8% with a dosage of 12 mg/day, which was four times higher than that of placebo (2.9%) [30] .
Both of LEVs and PERs have a unique mode of action to control seizures and are effective as adjunctive therapy for pharmacoresistant epilepsy. However, if patients have irritability, side effects of LEVs and PERs may be accentuated, leading to discontinuation of those agents. In this situation, patients with uncontrolled seizure may lose the chance to experience the efficacy of new drugs. Regarding this issue, clinicians should acknowledge irritability in epilepsy patients, identify its risk factors, and manage them appropriately. These procedures will reduce drug failure when clinicians administer AEDs with negative psychotropic profiles, especially irritability and aggression.
This study has some limitations. First, participants were recruited at a tertiary-care hospital, and predictors of interictal irritability may differ between this population and the community population of PWE. Second, because of a cross-sectional design, we could not confirm the causal relationships between irritability and variables investigated. Therefore, a longitudinal study would enable investigation of changes over time, and the effects of specific interventions.
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